Leishmaniasis: an update of current pharmacotherapy

@article{Sundar2013LeishmaniasisAU,
  title={Leishmaniasis: an update of current pharmacotherapy},
  author={Shyam Sundar and Jaya Chakravarty},
  journal={Expert Opinion on Pharmacotherapy},
  year={2013},
  volume={14},
  pages={53 - 63}
}
Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL). The treatment of VL is challenging. The duration of treatment is long, and drugs are toxic thereby needing monitoring and hospitalization. Areas covered: Novel therapies such as single dose of liposomal amphotericin B (L-AmB) and multidrug therapy are important breakthrough for VL in the Indian subcontinent and have been recommended as the treatment… 

An update on pharmacotherapy for leishmaniasis

TLDR
There is an urgent need to implement a single-dose L-AmB or combination therapy in the Indian subcontinent for the treatment of post – kala-azar dermal leishmaniasis.

Current and emerging medications for the treatment of leishmaniasis

TLDR
A single dose of liposomal amphotericin B (L-AmB) and multidrug therapy are the best options for VL in the Indian subcontinent (ISC), while a combination of pentavalent antimonials and paromomycin remains the treatment of choice in Africa where efficacious and safe regimens are needed for HIV-VL coinfection.

Chemotherapeutics of visceral leishmaniasis: present and future developments

TLDR
An effective treatment and secondary prophylaxis of HIV-VL co-infection should be developed to decrease treatment failure and drug resistance.

Cutaneous Leishmaniasis: Treatment Options and Possibilities for Drug Repurposing

TLDR
The present review summarizes the current treatment options available for cutaneous leishmaniasis as well as some drugs on the horizon that show promising results in the treatment of cutaneous Leishmania.

Comment on: Leishmaniasis: an update of current pharmacotherapy

To the Editor We compliment the investigators at the Banaras Hindu University for their review about the challenges faced during treatment of leishmaniasis in different continents [1], but feel that

Leishmaniasis: treatment, drug resistance and emerging therapies

TLDR
As most patients with PKDL (post-kala-azar dermal leishmaniasis) are asymptomatic, it is important that shorter regimens are developed, which will encourage patients to opt for complete treatment.

Recent developments and future prospects in the treatment of visceral leishmaniasis

TLDR
Fexinidazole and PA-824 are new promising drugs which have shown encouraging results in preclinical studies and are being considered as potential treatments for visceral leishmaniasis.

Current approaches to visceral leishmaniasis treatment in solid organ transplant recipients

TLDR
This review is a practical guide for Visceral Leishmaniasis specific treatment in solid organ transplant recipients (SOT), including therapeutic options and assessment of therapy response.

Treatment of pediatric cutaneous leishmaniasis with liposomal amphotericin B

TLDR
It is thought that the L‐AmB dose used in this study is not an appropriate treatment option for the treatment of pediatric CL patients, and prospective studies with a large number of patients treated with higher doses of L-AmB and in whom the causative agents of CL were determined are needed.
...

References

SHOWING 1-10 OF 94 REFERENCES

Treatment of visceral leishmaniasis

  • S. Sundar
  • Medicine, Biology
    Medical Microbiology and Immunology
  • 2001
TLDR
The alkyl phospholipid compound miltefosine is the first effective oral compound for VL and is likely to be marketed soon.

[Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients].

TLDR
A traditionally effective, but moderately toxic drug (MA) has been almost fully replaced by a new compound (L-AmB) with negligible toxicity, in an epidemiologic context of disease reemergence, and results have shown a countrywide change in therapy.

Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled Trial

TLDR
It is demonstrated that miltefosine therapy is more effective than standard Sbv and safe for the treatment of CL caused by Leishmania braziliensis in Bahia, Brazil.

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.

  • S. SundarM. Rai H. Murray
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2008
TLDR
Treatment with single-dose L-AmB followed by 7-14 days of miltefosine is active against Indian kala-azar, and this short-course, sequential regimen warrants additional testing in India and in those regions of endemicity where visceral leishmaniasis may be more difficult to treat.

Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica

TLDR
Liposomal amphotericin B (L‐AmB) is efficacious and safe for treating visceral leishmaniasis but its role in treating various forms of CL is yet to be defined.

Liposomal amphotericin B for the treatment of visceral leishmaniasis.

  • C. BernJ. Adler-Moore J. Alvar
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2006
TLDR
Clinical trials and experience demonstrate high efficacy and low toxicity for liposomal amphotericin B (total dose, 20 mg/kg) in immunocompetent patients with VL, and the public health community should work to broaden access to preferential liposome amphoteric in B pricing by public sector VL treatment programs.

Treatment of Bolivian mucosal leishmaniasis with miltefosine.

  • J. SotoJ. Toledo J. Berman
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
TLDR
In this unrandomized trial, oral miltefosine was at least as effective as heroic doses of parenteral amphotericin B and should be the treatment of choice for mucosal disease in North and South America.
...